Anebulo Pharmaceuticals (NASDAQ: ANEB)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-11 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-21 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Anebulo Pharmaceuticals (NASDAQ: ANEB) through any online brokerage.
Other companies in Anebulo Pharmaceuticals’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Terns Pharma (NASDAQ:TERN), Lipocine (NASDAQ:LPCN) and Longboard Pharmaceuticals (NASDAQ:LBPH).
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Ladenburg Thalmann on Wednesday, July 27, 2022. The analyst firm set a price target for 6.00 expecting ANEB to rise to within 12 months (a possible 48.15% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Anebulo Pharmaceuticals (NASDAQ: ANEB) is $4.05 last updated August 15, 2022, 8:00 PM UTC.
There are no upcoming dividends for Anebulo Pharmaceuticals.
Anebulo Pharmaceuticals’s Q1 earnings are confirmed for Friday, November 11, 2022.
There is no upcoming split for Anebulo Pharmaceuticals.
Anebulo Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.